The Latest
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
New startup Kalexo Bio launched with rights to an RNA drug for heart disease that came via a potentially $1 billion deal with China's Mabwell Bioscience.
Updated 6 hours ago -
wirestock via envato
Sponsored by AltorWorking smarter: best practices for thermal modeling in cold chain packaging design
Smarter cold chain design starts with thermal modeling—learn best practices here.
-
Stock via Getty Images
Roivant pill succeeds in rare inflammatory disease trial
A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.
-
Alexander Ford via Getty Images
Startup launchesOllin debuts with $100M and plans to challenge top-selling eye drugs
Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.
-
Pixelimage via Getty Images
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding.
-
yodiyim via Getty Images
Startup launchesFormer CinCor execs reunite to helm new biotech startup
Led by former founders of a biotech AstraZeneca acquired in 2023, AllRock Bio is starting out with a drug licensed from Sanofi that’ll be tested against pulmonary arterial hypertension.
-
Adeline Kon/BioPharma Dive
Deep Dive // Emerging biotechBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
LB Pharmaceuticals’ $285 million offering is the first sizable IPO since February and the largest for a biotech company this year, according to BioPharma Dive data.
Updated Sept. 10, 2025 -
Sedat Suna via Getty Images
Novartis dives deeper into protein degraders with second Monte Rosa deal
The company’s new partnership with the "molecular glue” drug developer is broad, focused on immunology and could be worth up to $5.7 billion.
-
Permission granted by Radiology Partners
Deep DiveFoundation models are medtech’s newest trend. But what are they?
The AI models, which are built on massive datasets and can be adapted to multiple tasks, have become a part of medtech companies’ lexicon in the past few years.
-
eranicle via Getty Images
ATyr shares plunge on trial miss in inflammatory lung disease
The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.
-
aprott via Getty Images
Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology
Early academic research suggests various ways weight loss drugs could have an impact in cancer care.
-
Daniel Tadevosyan via Getty Images
News roundupTakeda poaches top Lilly exec; Maze soars on early PKU drug data
Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in court.
-
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive // Patent thicketsDrug patents protect pharma profits. Track when they’ll expire.
AbbVie reached legal settlements delaying the arrival of generic versions of Rinvoq until 2037, enabling four more years of exclusivity for a drug that banked about $6 billion in sales in 2024.
Updated April 9, 2025 -
Retrieved from Vinay Prasad on May 08, 2025
Trump administrationPrasad regains role as FDA’s top doctor, scientist
An HHS spokesperson confirmed Prasad's reappointment as chief medical and scientific officer, one month after his surprising return to the agency as CBER director.
-
Stock via Getty Images
Child dies in Capsida study of rare disease gene therapy
Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s therapy for a rare neurodevelopmental disorder.
Updated Sept. 11, 2025 -
Sarah Silbiger via Getty Images
FDA shares guidance to drugmakers developing non-opioid pain medicines
The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid addiction crisis.
-
Alamy
Obesity drugsNovo Nordisk to lay off 9,000 workers in major restructuring
The drugmaker’s new CEO said the moves will help the company be more agile as it deals with competition in the obesity market and a declining stock price.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech’s M&A outlook is uncertain. Track the deals that are happening here.
Novartis will acquire Tourmaline Bio in a $1.4 billion deal that hands the Swiss pharma an experimental heart medicine ready for Phase 3 testing.
Updated Sept. 9, 2025 -
Alamy
IPO windowLB Pharmaceuticals raises $285M in first major biotech IPO since February
LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for large IPOs in years.
-
Courtesy of Johnson & Johnson
FDA clears J&J’s drug-device combo for bladder cancer
J&J executives have said they expect the therapy, Inlexzo, to become a future blockbuster and generate sales that significantly outstrip Wall Street forecasts.
-
Daniel Tadevosyan via Getty Images
News roundup
Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership
Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug conjugate.
-
jetcityimage via Getty Images
Emerging biotechLilly to give biotech startups access to AI tools
Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.
-
Andrew Harnik via Getty Images
Trump administrationRFK Jr. is remaking HHS. Track the changes here.
Following an executive order from President Trump, the FDA plans to “aggressively deploy its available enforcement tools” to police direct-to-consumer drug ads.
Updated Aug. 28, 2025 -
Sedat Suna via Getty Images
Novartis to gain heart drug in $1.4B deal for Tourmaline Bio
Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into Phase 3 testing for heart disease.
-
Dragos Condrea via Getty Images
Brain drug revivalA new class of sleep drugs draws Wall Street’s attention
Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.
-
Mohammed Haneefa Nizamudeen via Getty Images
New Summit data clouds approval pathway in lung cancer
A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.
